Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI6570 in Type 2 Diabetes
NCT03654313Phase 1Completed
- Sponsor
- MedImmune
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of golocdacimab in atherosclerosis and cardiovascular disease (CVD) (4 arms), sponsored by MedImmune. Primary endpoint: Number of subjects with adverse events and serious adverse events. Started Sep 2018; status: completed.
02
Drugs
golocdacimab
03
Conditions
atherosclerosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03654313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654313.